Home Latest Articles
Latest Articles
  • Jiahua LENG, Ziyi LIN, Jianwei XUAN
    World Clinical Drug. 2023, 44(1): 51-58.
    Objective

    To estimate the potential health benefits of pembrolizumab for the second-line esophageal squamous cell carcinoma patients with programmed death-ligand 1 positive [combined positive score (CPS)≥10] in China from 2021 to 2025, in order to provide reference for scientific evaluation of clinical benefits of innovative antitumor drugs and effective allocation of health resources.

    Methods

    A patient flow calculation model and a partitioned survival model were built to calculate the number of patients with second-line esophageal squamous cell carcinoma who might be treated with pembrolizumab from 2021 to 2025. A partitioned survival model was established to estimate the incremental benefits of life year (LY) and quality-adjusted life years (QALYs) gained of an average patient using pembrolizumab compared with regular chemotherapies. The total potential gains in LY and QALYs of the second-line esophageal squamous cell carcinoma patients in China from 2021 to 2025 was calculated by discounting at 5% annually.

    Results

    In the next 5 years, a total of 43 439 patients could benefit from pembrolizumab. The average lifetime LY and QALYs increments per patient with pembrolizumab are 1.603 and 1.442, respectively. The total increments of LY and QALYs in 5 years gained by the introduction of pembrolizumab were 63 026 and 56 696, respectively.

    Conclusions

    Programmed death-1 inhibitor is expected to bring considerable survival and quality-of-life benefits for patients with esophageal squamous cell carcinoma in China.

  • Lisa JIN, Bin PENG, Dayu WU, Xuelian YANG, Xiaowen ZHOU, Longxuan LI, Bincang HUANG, Wei CHEN
    World Clinical Drug. 2023, 44(1): 59-65.
    Objection

    To investigate the correlation between plasma microRNAs (miR) and cerebral collateral circulation in patients with carotid stenosis.

    Methods

    In this cross-sectional study, 60 patients with carotid artery stenosis over 30% confirmed by ultrasound screening at Shanghai Gongli Hospital from Jan 2017 to Oct 2018 were enrolled. Cerebral digital subtraction angiography was used to evaluate the establishment of collateral circulation. Real-time fluorescence quantitative polymerase chain reaction was used to determine the expression levels of miR-92-3p, miR-15a-3p, miR-16-3p, miR-126-3p, miR-210-3p and miR-132-3p. The general clinical data, degree of carotid stenosis and the relationship between the establishment of cerebral collateral circulation and plasma miR level was compared among the three groups. Multivariate logistic regression and receiver operating characteristic curve (ROC) were used to analyze the predictive ability of plasma miR levels to establish cerebral collateral circulation in patients with carotid stenosis.

    Results

    According to the Guidelines for Evaluation and Management of Cerebral Collateral Circulation in Ischemic Stroke (2017) by the Chinese Medical Association, 17 cases were included in the 30% - 50% carotid stenosis group, 21 cases in the 50% - 70% carotid stenosis group, and 22 cases in the 70% - 99% carotid stenosis group. After adjusting for gender, drinking history and degree of carotid stenosis, logistic regression results showed that miR-92A-3p was negatively correlated with collateral circulation [(odds ratio, OR)=0.21]. miR-126-3p, miR-132-3p and miR-210-3p were positively correlated with collateral circulation (OR were 6.10, 1.91 and 3.09). ROC suggested that these four miR had predictive efficacy for collateral circulation establishment (area under curve: 0.918 - 0.942), among which miR-126-3p had the highest efficacy.

    Conclusion

    The expression levels of miR-92, miR-126, miR-210 and miR-132 in plasma have certain diagnostic value for establishing cerebral collateral circulation in patients with carotid stenosis.

  • Hui PAN, Chenyang SHI, Guorong FAN, Yuanjun TANG
    World Clinical Drug. 2023, 44(1): 66-72.
    Objective

    To investigate the distribution of blood concentration and liver and kidney function of tacrolimus in patients after liver transplantation.

    Methods

    The clinical data of 66 patients who underwent orthotopic liver transplantation in Shanghai General Hospital from September 2015 to October 2019 and were treated with tacrolimus regimen were retrospecticely collected, as well as the blood trough concentration of tacrolimus and liver and kidney function at different periods.

    Results

    The average blood concentration of tacrolimus in 66 patients whthin 30 days was (7.39±3.18) ng/ml, and 39% of patients had a blood concentration of 6—10 ng/ml. The average blood concentration in 90 days was (6.32±3.09)ng/ml, and 58% of patients had blood concentration was 4—8 ng/ml. The average blood concentration in 180 days was (6.43±3.03)ng/ml, and 55% of patients had blood concentration was 4—8 ng/ml, which was lower than the reference concentration of domestic guidelines. The alanine aminotransferase and aspartate aminotransferase in 66 patients gradually decreased to normal levels within 30 days after surgery, and remained basically within the normal range at 180 days after surgery, with no statistically significant difference compared with that before surgery. Serum creatinine (Scr) recovered within 30 days after surgery, but at D180 Scr was significantly higher than that before surgery, with statistical difference (P<0.05). In tacrolimus group, Scr was significantly different from that before operation at D180 (P<0.05). In tacrolimus+sirolimus group, Scr did not differ from that before surgery at D180.

    Conclusion

    Low tacrolimus effective concentration after liver transplantation can exert anti-rejection therapy and not cause adverse reactions. Long-term use of tacrolimus is associated with cumulative renal injury.

  • Xiaoli SONG, Huiqin YANG, Yueliang XIE
    World Clinical Drug. 2023, 44(1): 73-76.
  • Yimei TAN, Yi ZHAO, Wei LIU, Yanyun MA
    World Clinical Drug. 2023, 44(1): 77-82.

    The skin barrier is an important barrier system of the human body, which is crucial to the maintenance of body health, and its homeostasis is strictly and precisely regulated. Skin barrier damage is the main characteristic of problematic skin, as well as the key inducement and typical accompanying symptoms of a variety of skin diseases. An in-depth understanding of the formation and regulation mechanism of the skin barrier will not only help to establish repair strategies but also reveal the occurrence and development mechanism of related skin diseases. Therefore, this article reviewed on the skin barrier structure and regulation of the molecular mechanism. In the perspective of omics, this paper emphasized the research progress of barrier regulation related genomics, epigenomics, transcriptomics, proteomics and metabolomics, and summarized the target and strategy of barrier repair based on different omics levels, revealed the mechanism of barrier formation and the basis of repair, in order to provide a theoretical basis for the repair of the skin barrier and the precise prevention and control of related skin diseases.

  • Wenqing ZHANG, Xuanxuan WANG, Anqi HUANG, Di XIE, Mengru XIN, Weizhi LIU, Hankun HU
    World Clinical Drug. 2023, 44(1): 83-89.

    Traditional toxicological studies of drugs mostly focused on experimental animals. However, animal experiments were susceptible to many factors, and it was difficult to completely simulate the toxic reaction of drugs in human body, and there was a lack of sensitivity and specificity to predict drug toxicity. Organ-on- chip technology had attracted increasing attention by constructing heart, liver, kidney and other organ chips to carry out toxicological evaluation in vitro. In this paper, the research status, challenges and application prospects of the new technology in drug toxicological evaluation were reviewed, in order to provide reference for the development and application of this technology.

  • Yang FU, Hongsheng WANG, Fengjuan LU
    World Clinical Drug. 2023, 44(1): 90-93.

    Acute hematogenous osteomyelitis in children is the most common disease of skeletal muscle system infection in children. It is mainly caused by Staphylococcus aureus infection and has a strong destructive effect. Delayed treatment may lead to deep vein thrombosis, endocarditis and septic shock and other complications. In the long term, it may lead to bone ischemic necrosis, pathological fracture, deformity, activity restriction and affect growth and development and other sequelae. Therefore, early and accurate diagnosis and timely and reasonable treatment are very important. This article reviews the research progress in diagnosis and drug treatment of acute hematogenous osteomyelitis in children, in order to improve the standardization and therapeutic effect of treatment.

  • Ning WANG, Yingyun GUAN, Xiaolan BIAN
    World Clinical Drug. 2023, 44(1): 94-100.
    Objecitve

    To understand the current status of the application of sacubitril valsartan in hypertensive patients in China and evaluate its rationality in clinical application.

    Methods

    Through the prescription review system of the clinical pharmacy intelligent platform, all outpatient prescriptions with hypertension diagnosed and Sacubitril Valsartan used during the period from June 1 2021 to June 30 2022 were extracted, and the collected data were statistically and analyzed.

    Results

    A total of 17 100 qualified prescriptions were extracted. The top three departments in the number of prescriptions were hypertension department, cardiology department and nephrology department. Hypertension combined diseases were mainly cardiac insufficiency and renal insufficiency. Through the initial system screen and manual review, 1 033 unreasonable prescriptions were found, accounting for 6.04% of the total number of prescriptions. The main unreasonable problems were repeated drugs and the unreasonable use of combined drugs.

    Conclusion

    The population of application of Sacubitril Valsartan in hypertensive patients is increasing day by day, but the rationality of medication needs to be further improved. Pharmacists should strengthen the publicity and education of rational medication for doctors and patients to ensure the safety and effectiveness of new antihypertensive drugs in clinical application.

  • Na CHEN, Qiurong TAN
    World Clinical Drug. 2022, 43(12): 1521-1526.

    Rational drug use is a key component of medical safety. Participation in the consultation of infectious diseases is the primary opportunity for clinical pharmacists to integrate into the clinical treatment. With the deepening of the consultation work, clinical pharmacists play an increasingly important role in the treatment of adult infectious diseases. However, there is a serious lack of participation in the formulation and adjustment of anti-infective programs for newborns, especially premature infants. By collecting the literature reports of clinical pharmacists participating in the anti- infective treatment of premature infants published in China, this paper summarized the effect and experience of clinical pharmacists participating in the anti-infective consultation of premature infants, and expounded the experience of clinical pharmacists integrating into the treatment team from the professional characteristics, giving full play to their advantages and due roles.

  • Wen ZHU, Yanyan SUN
    World Clinical Drug. 2022, 43(12): 1527-1533.

    Preterm infants are at high risk of infection because of their immature organs and immune system. There were many risk factors of infection in premature infants, including gestational age, birth weight, gender, Apgar score, feeding intolerance and underlying diseases. Maternal factors were included, such as multifetation, chorioamnitis, amniotic fluid contamination, premature rupture of membranes, cesarean section, vaginal rupture bacteria and diseases of pregnancy. Iatrogenic factors included invasive procedures, use of hormones and broad-spectrum antibiotics, long-term parenteral nutrition, and longer hospital stay. This paper summarized the risk factors and prevention measures of premature infant infection, in order to arouse clinical attention to premature infant infection, strengthen hospital management and family monitoring, reduce the risk of infection, reduce the mortality of premature infants.

News